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Osteosarcoma (OSA) is the most common primary malignant bone tumor, usually arising in the long bones of children and
young adults. here are diferent subtypes of OSA, among which we ind the conventional OS (also called medullary or central
osteosarcoma) which has a high grade of malignancy and an incidence of 80%. here are diferent subtypes of high grade OS like
chondroblastic, ibroblastic, osteoblastic, telangiectatic, and the small cell osteosarcoma (SCO). In this study, for the irst time,
we have isolated, established, and characterized a cell line of cancer stem cells (CSCs) from a human SCO. First of all, we have
established a primary inite cell line of SCO, from which we have isolated the CSCs by the sphere formation assay. We have proved
their in vitro mesenchymal and embryonic stem phenotype. Additionally, we have showed their neoplastic phenotype, since the
original tumor bulk is a high grade osteosarcoma. his research demonstrates the existence of CSCs also in human primary SCO
and highlights the establishment of this particular stabilized cancer stem cell line. his will represent a irst step into the study of
the biology of these cells to discover new molecular targets molecules for new incisive therapeutic strategies against this highly
aggressive OSA.
1. Introduction
Inside the heterogeneous group of sarcomas we ind the
osteosarcoma (OSA). OSA is one of the most common
primary bone tumors which occurs in childhood and in
youth [1–3]. he incidence of this cancer is about 2 cases per
million persons, per year [4, 5].
Principle sites, which are involved by OSA, are the meta-
physeal regions of the long bones of the extremities, charac-
terized by a rapid bone development during the adolescence.
he most common sites injured are distal femur, proximal
tibia, and proximal humerus [6–9]. Nowadays, despite the
fact that multimodality treatment approach has increased the
survival rate from 50% in adults to 70% in children, there
is always a large proportion which sufers from recurrences
and dissemination of the primary tumor. Unfortunately,
the survival rate for these people and for whom present
micrometastases at the moment of the diagnosis remains
poor (<20%) [10–12].
he World Health Organization has classiied the OSA
as malignant bone tumor which presents several diferent
subtypes in relation to the histology and to the area of interest
of the primary tumor bulk [13].
Between the diferent typologies there is also the low-
grade OSA, but the major types of OSA are high grade
tumors, which include the small round cell osteosarcoma
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Figure 1: Small round cell osteosarcoma.he tumor is composed of
a uniform population of round cells with focal production of osteoid
matrix (H&E). Observation in brightield. Original magniication:
10x.
(SCO). SCO is an extremely rare form of OSA with an
incidence of 1.3% of all diagnosed cases for OSA [14, 15].
Histologically the SCO is composed of small round cells
with malignant phenotype, necrotic areas, and island of
osteoid matrix in the stroma (Figure 1).
In any cases has been reported the production of the
chondroid, too [15–19]. SCO mainly involved the femur but
it can occur in all portions of the skeleton. his bone tumor
can be confused by the other primary bone tumor, Ewing’s
Sarcoma (ES). his is possible only when the typical osteoid
matrix produced by the tumor cells is not visible in the
portion of biopsy. In this case, it is possible to diagnose the
SCO, evaluating the immunohistochemical (IHC) expression
of CD99 and SATB2, two markers of osteoblastic diferentia-
tions which are not expressed in cells of ES [4, 20–22].
he importance to make a correct diagnosis is related
to the diferent kind of therapies which can be used against
these two tumors, and which can inluence the prognosis.
Nowadays, as the other typologies of OSA, the therapeutic
approach is multidisciplinary (surgery, chemotherapy, and
radiotherapy) but unfortunately this does not permit having
a good prognosis.
Additionally, it has been reported that the median sur-
vival time for a patient who did not have only the surgery
but also the chemotherapy treatment is 13 years from the
diagnosis of the cancer.
While this value is of 1.4 years for patients who did not
have the surgery excision of the tumor bulk, in all these
cases recurrence of the primary tumor and the appearance
of metastases are oten present and the principal site of SCO’s
metastases is the lung, as the other OSA [14, 23, 24].
Recent studies have also indicated the presence in bone
sarcomas of a subpopulation of particular cells, called CSCs
which result to be responsible to maintain and to regenerate
the tumor bulk ater the conventional multidisciplinary
neoadjuvant therapy [25–30]. Consequently, CSCs should be
present in all of the types of OSA, which are resistant to
chemotherapy, like the SCO. Several studies have evaluated
the presence of this subpopulation in OSA [31–34].
Since we have had the possibility of establishing a inite
cell line from a human fresh biopsy of SCO, we have isolated
and characterized a cell line of CSCs, in order to investigate
the presence of CSCs in SCO. Hence, for the irst time a CSCs
line of small round cell osteosarcoma has been established.
2. Materials and Methods
he whole study was conducted following the approval
of Florence University Hospital Ethics Committee (Rif. N.
141/12) and has therefore been performed in accordance
with the ethical standards laid down in 1975 Declaration of
Helsinki and its later amendments Informed Consent for
tissue collection, use, and storage of the samples was obtained
from the donor at AOUC.
2.1. Primary Osteosarcoma Cell Culture. Primary SCO cell
culture has been produced in our laboratory from a fresh
sample of SCO biopsy collected at the “Unita` Ortopedia
Oncologica e Ricostruttiva”, AOUC Careggi, Florence. he
biopsy, obtained by the method of the needle aspiration, was
immediately placed in a culture medium supplemented by
100 IU/mL penicillin and 100 �g/mL streptomycin, pH 7.4,
transported to the laboratory and processed.
he SCO primary cell culture, from the SCO tissue sam-
ple, has been set up ater enzymatic treatment in Ham’s F12
Coon’s modiicationmedium (Sigma-Aldrich, St. Louis, MO)
with collagenase type II (Sigma-Aldrich, St. Louis,MO) at 37∘
and followed by mechanical dispersion. Cells were cultured
as monolayer in Ham’s F12 Coon’s modiication medium
supplemented with 10% of fetal bovine serum (FBS) in a
modiied atmosphere of 5% CO2 in air at 37
∘C. he culture
medium was changed every three days. he SCO cell culture
was signed as OSA3. When cells grew to approximately 80–
90% conluence, they were subcultured or harvested using
Trypsin-EDTA.
2.2. Sphere Formation Assay. his is an in vitro assay used
to identify and isolate cancer stem cells (CSCs) from a
cancer cell line. At the 90% conluence in Ham’s F12 Coon’s
modiication medium, monolayer cells were dissociated
with Trypsin-EDTA into a single-cell suspension. he cells
were inoculated into sarcosphere growth medium (SGM)
supplemented with 2% sterile methylcellulose (MC) at a
density of 4 × 104 cells/well in ultra-low attachment six-
well plates (Corning Inc., Corning, NY). SGM medium
consists of 2x Ham’s F12 Coon’s modiication medium sup-
plemented with progesterone (20 nM), putrescine 100 �M,
sodium selenite (30 nM), transferrin (25 �g/mL), insulin
(20�g/mL), the human recombinant epidermal growth factor
(EGF; 10 ng/mL), and the basic ibroblast growth factor (b-
FGF; 10 ng/mL) as described by Gibbs et al. [35]. All reagents
were purchased by Sigma-Aldrich. Fresh aliquots of b-FGF
and EGF were added every three days.
Ater 28 days of culture, spherical colonies formed by >50
cells were deined as “sarcospheres” and were quantitated by
inverted phase contrast microscope and ater that they were
isolated and plated in normal attachment 60mm diameter
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Figure 2: Biopsy sample of small round cell osteosarcoma. Biopsy
sample of small round cell osteosarcoma by surgical resection of two
small parts of the tumor.
Figure 3: Primary cultures of small round cell osteosarcoma.
Observation in phase contrast of primary cells of small round cell
osteosarcoma obtained ater 24 h from the mechanical disgregation
of the biopsy sample. Original magniication 10x. Bar size: 100 �m.
tissue culture plates with normal growth medium. he cells
isolated from sarcospheres were signed as osteosarcoma
cancer stem cells (OSA3-CSCs). When OSA3-CSCs have
reached approximately 90% conluence, they were harvested
and subcultured into a 100mm diameter tissue culture plate.
An additional sphere formation assay has been set up on
OSA3-CSCs to investigate their ability of self-renew through
secondary sphere formation. he cells isolated from this
additional assay have been signed as OSA3-CSCs II.
2.3. Osteosarcoma Cancer Stem Cell Culture. OSA3-CSCs
and the OSA3-CSCs II cell lines were cultured in a speciic
growth medium (GM), which is composed of Ham’s F12
Coon’s modiication medium supplemented with 10% FBS,
100 IU/mL penicillin, 100 �g/mL streptomycin, and 1 ng/mL
b-FGF.he medium was refreshed twice a week and the cells
were used for cryopreservation and for in vitro analyses to
characterize their stem-like phenotype upon reaching 5 ×
103 cells/cm2.
2.4. Cell Line Characterization. he characterization of the
cancer stem cell phenotype of the OSA3-CSCs cell line was
performed by studying the doubling time, the sphere forma-
tion assay, the sot agar assay, the colony forming unit assay,
the adipogenic and osteogenic diferentiation, the aldehyde
dehydrogenase activity analysis, the low cytometric analyses,
the immunoluorescence staining, and the gene expression.
To conirm the stem phenotype of the second generation
of cancer stem cells, the OSA3-CSCs II cell line has been
characterized by several analyses (i.e., colony forming unit
assay (CFU), diferentiation stainings, immunoluorescence
stainings, and gene expression analyses).
2.4.1. Analysis of Cell Proliferation. OSA3-CSCs were plated
in 100mm diameter dishes at the concentration 10,000 cells/
dish. Ater 24 hours, GM was replaced with Ham’s F12
Coon’s modiication medium with 1.5% FBS and maintained
in culture for three days. At the end, Coon’s medium was
replaced by Coon’s medium with 10% FBS. he number
of cells was evaluated at 0, 2, 4, and 6 days counting by
hemocytometer chamber. he growth curve was plotted
and the cell population doubling time was calculated. Each
experimental point has been performed in triplicate.
2.4.2. Sot Agar Colony Forming Assay for Neoplastic Trans-
formation. he sot agar assay is an anchorage independent
growth assay in sot agar, which is considered the most rig-
orous assay in vitro for detecting and proving the malignant
transformation of cells.We have performed the agar sot assay
on the primary cell line of SCO (OSA3), on the OSA3-CSCs,
on the human osteosarcoma cell lines Saos-2 purchased from
American Type Culture (ATCC, Manassas, VA), and on the
mesenchymal stem cell line of preadipocytes (PA).
A 35mm dish was coated with 1% sterile agar prepared
in culture medium maintained liquid at 47∘C. he dish
was immediately cooled. he cell lines in growth phase
were detached, suspended in medium, diluted to double the
required inal concentration, and maintained at 37∘C. 0.33%
agar was prepared in medium and maintained at 45∘C.
Cell suspensionwasmixedwith an equal volume of 0.33%
agar, distributed into the agar coated dish to obtain a inal
concentration of 2,500 cells/dish, and immediately cooled.
he cells were cultured at 37∘C in humidiied air with 5%
CO2 for 4 weeks until the formation of colonies and their
growth. Colonies formed per dishwere observed and counted
in phase contrast microscopy (Axiovert 200, ZEISS). his
experiment has been performed in triplicate.
2.4.3. Colony Forming Unit Assay. OSA3-CSCs and OSA3-
CSCs II lines were plated in 100mm diameter dishes. When
they had, respectively, reached 80% conluence, they were
detached with Trypsin-EDTA and plated in 100mmdiameter
dishes with a inal concentration of 450 cells/dish. he cells
were cultured inHam’s F12 Coon’smodiicationmediumwith
20% FBS, 100 IU/mL penicillin, and 100 �g/mL streptomycin
at 37∘C in humidiied air with 5% CO2 for 4 weeks until
the formation of colonies. Colonies formed per dish were
stained with Toluidine Blue. he colored colonies have been
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Figure 4: Small round cell osteosarcoma inite cell line. Observation in phase contrast of cell line of OSA3 ater 15 days (a) and ater 1 month
(b) from mechanical disgregation.
�-actin
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Figure 5: Expression of the SATB2 and EWSR1 genes in OSA3. RT-
PCR show the expression of EWSR1 and of SATB2 as characteri-
zation of the OSA3 line as properly a cell line of small round cell
osteosarcoma.
Figure 6: Sarcosphere assay on OSA3. Ater 24 h from the start of
the assay, cells appear loating and isolated from each other (cells are
indicated by the black/red arrows). Observation in phase contrast.
Original magniication: 10x.
counted using an invertedmicroscope (Axiovert 200, ZEISS).
he CFU eiciency has been calculated according to the
following formula: (number of colonies formed/number of
cells seeded) ∗ 100. his experiment has been performed in
triplicate.
2.4.4. Osteogenic Diferentiation. OSA3-CSCs and OSA3-
CSCs II cell lines were plated on 24-well plates at a cell density
of 1 × 104 cells/cm2 in GM and grown to 80–90% conluence
in each well. Aterwards, the medium was switched to
osteogenic medium (OM): Ham’s F12 Coon’s modiication
medium supplemented with 10% FBS, 100 IU/mL penicillin,
100 �g/mL streptomycin, 10 nM dexamethasone, 0.2mM
sodiumL-ascorbyl-2-phosphate, and 10mM�-glycerol phos-
phate. he medium was refreshed every three/four days.
he osteogenic diferentiation was stopped at 21 days to
evaluate the osteoblastic phenotype. he main characteris-
tics of osteoblastic phenotype are the presence of alkaline
phosphatase (ALP) and of extracellular calcium mineralized
deposits.
he cells were washed with DPBS (LONZA) (two times),
ixed in 4% paraformaldehyde (PFA)/DPBS for 15min, and
washed with ultrapure water (three times). Ater that, for
alkaline phosphatase (ALP) staining, the cells were washed
with DPBS (two times) and stained with a speciic dye
mixture.
his mixture is composed of Solution A (5mg naphthol-
AS-MX phosphate sodium salt dissolved in 1mL dimethyl
sulfoxide) and Solution B (40mg Fast Blue BB dissolved in
49mL Tris-HCl Bufer 280mM, pH 9.0) which are mixed
together forming Solution C. 1mL of Solution C was added
for each well for 30min at 37∘C in humidiied air with 5%
CO2. ALP+ cells were stained in blue and nuclei were coun-
terstained in red with Propidium Iodide. For mineralization
staining, the cells were washed with DPBS (two times), ixed
in 4%PFA/DPBS for 15min, andwashedwith ultrapurewater
(three times). Calcium mineralized deposits were stained for
2min with Alizarin Red S, pH 6.0, and rinsed with ultrapure
water (three times). Hence, calcium mineralized deposits
were stained in red-orange. ALP+ cells and calcium min-
eralized deposits were observed in brightield microscopy
(Axiovert 200, ZEISS).
2.4.5. Adipogenic Diferentiation. OSA3-CSCs and OSA3-
CSCs II cell lines were cultured with a speciic adi-
pogenic medium (AM): in Ham’s F12 Coon’s modiication
medium supplementedwith 10% (FBS), 100 IU/mLpenicillin,
100 �g/mL streptomycin and 1 �M dexamethasone, 1 �M
bovine insulin, and 0.5mM isobutylmethylxanthine (IBMX).
he medium was refreshed twice a week. he expression of
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Figure 7: Sarcosphere assay on OSA3 at 14 and at 28 days. (a) Ater 14 days from the start of the assay, several small spherical colonies can
be observed.he sarcospheres (indicated by the yellow arrows) appear loating in the medium or slightly settled down into the bottom of the
well. (b) Ater 28 days big spherical colonies can be observed. Observation in phase contrast. Original magniication: 20x. Bar size: 100 �m.
(a) (b)
Figure 8: Sarcosphere ater isolation. (a) Sarcospheres fromOSA3 cell lines showed a beginning of adherent expansion by reintroduction and
reculturing in monolayer, adherent conditions at 48 hours from the isolation. (b) At 7 days ater the isolation sarcospheres showed adherent
expansion by reintroduction and reculturing in monolayer, adherent conditions. Observation in phase contrast. Original magniication: 20x.
Bar size: 100 �m.
Figure 9: Cancer stem cell line OSA3-CSCs. Observation in phase
contrast. Original magniication: 10x. Bar size: 100 �m.
the adipogenic phenotype was evaluated on cells cultured in
AM or GM for 30 days by Oil Red O staining. he colored
cells were observed in brightield microscopy (Axiovert 200,
ZEISS).
2.4.6. Aldehyde Dehydrogenase Activity Assay. he aldehyde
dehydrogenase (ALDH) activity has been evaluated by an
ALDH activity colorimetric assay kit (Sigma-Aldrich, St.
Louis, MO) on the OSA3-CSCs and on a inite cell line
of ibroblast, used as negative control. his kit quantiies
the ALDH enzymatic activity by absorbance reading at
450 nm (VICTOR3, Perkin Elmer). he cell line was grown
in 100mm diameter dishes. When the cells had reached
100% conluence, they were detached with Trypsin-EDTA,
centrifuged, resuspended in ALDH assay bufer, transferred
in an ice cold 5ml Dounce homogeniser, and disrupted. Ater
that we have proceeded as described in the manufacturer’s
protocol. All tests have been done in triplicate.
2.4.7. Flow Cytometry Analysis. For low cytometry, OSA3,
OSA3-CSCs, and PA were detached from tissue dishes with
Trypsin-EDTA. Cells were suspended at a density of 1 ×
105 cells/mL in 100�L of phosphate-bufered saline with 1%
bovine serum albumin and 0.1% sodium azide (Miltenyi)
[36]. he antibodies were used according to manufacturer’s
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Figure 10: Growth curve. Graphical representation in linear regres-
sion of the kinetics of growth for OSA3-CSCs line cultured in GM
(� = 0.0018� + 3.956; �2 = 0.99). Experiment is carried out in
triplicate.
instruction. he marked cell suspensions in 800�L were
analyzed in a low cytometer (CyFlowSpace, PARTEC).
2.4.8. Immunoluorescence Staining. Immunoluorescence
staining on OSA3-CSCs ixed in 4% PFA/DPBS was used
to investigate the mesenchymal stem cells (MSCs) markers,
using primary antibody to CD44, CD45, and CD105, and to
investigate the embryonic stem cells (ESCs) and the CSCs
markers, using, respectively, primary antibody to Nanog,
POU5F1, SOX2, KLF4, LIN-28A, and PROM1 (CD133)
and CD117. Ater ixation cells were permeabilized by 0.2%
Triton X-100/DPBS at 37∘C in humidiied air with 5% CO2.
Cells were washed three times with DPBS and were treated
by RNase diluted 1/1000 with 2% BSA/DPBS at 37∘C in
humidiied air with 5% CO2. Ater that cells were washed
three times in DPBS and stained with the mouse primary
antibodies (1 : 5; anti-CD44 (Invitrogen); 1 : 5; anti-CD45
(Abcam); 1 : 5; anti-CD105 (Invitrogen); 1 : 5; anti-POU5F1
(Sigma); 1 : 10; anti-PROM1 (Miltenyi)) and with the rabbit
primary antibodies (1 : 5, anti-Nanog (Abcam); 1 : 5; anti-
SOX2 (Abcam); 1 : 5; anti-LIN28A (Abcam); 1 : 5; anti-KLF4
(Abcam); 1 : 5; anti-CD117 (Bioss)). Ater incubation in a
humid environment at 4∘C over night the primary antibodies
were removed and cells were stained with the secondary
antibody (1 : 300; goat anti-Mouse Alexa Fluor 635 IgG
(H+L), Life Technologies; 1 : 300; goat anti-rabbit IgG
(H+L) Superclonal Secondary Antibody, Alexa Fluor 488,
Invitrogen) in the dark in a humid environment at room
temperature for 45 minutes. hen cells were washed several
times by DPBS and counterstained for nuclei with Propidium
Iodide (1 : 100 in DPBS). As negative internal control we used
cells marked with only the secondary antibody. Stained cells
were examined with 20x at room temperature on a Laser
Scanning Confocal Microscopy (LSM 5109 Meta, ZEISS).
2.5. Gene Expression Analyses by Real-Time PCR. mRNA
of OSA3, OSA3-CSCs, and OSA3-CSCs II was prepared
by Trizol Reagent (Invitrogen, USA). Reverse transcription
and Real-Time PCR (RT-PCR) analysis were carried out as
described using speciic primers following themanufacturer’s
protocol. �-actin was used as internal control.
First of all, we have analyzed the expression of SATB2 and
of EWSR1 genes to analyze the phenotype of the primary cell
line of small round cell osteosarcoma, OSA3. Ater that we
have proceeded to characterize theCSCs lines.he expression
of the ESCs and of the pluripotency marker genes (POU5F1,
Nanog, SOX2, KLF4, LIN-28A, and MYC) was evaluated on
OSA3, OSA3-CSCs, and OSA3-CSCs II lines.
At the same time on OSA3 and OSA3-CSCs lines have
been evaluated also the expression of the cancer stem cells
marker genes (prominin 1 (PROM1), aldehyde dehydroge-
nase 1 family, member A1 (ALDH1A1), and CD34 antigen
(CD34)) and the expression of themarker genes formigration
and metastasis (EZR and AXL).
All these analyses were set up on CSCs cell lines cultured
in GM at the 4th passage of subculture ater the isolation of
the sarcospheres and on the primary cell line cultured in GM
at the 1st passage of subculture.
he expression of the adipogenic phenotype in theOSA3-
CSCs was evaluated on cells cultured in GM or AM for
30 days by RT-PCR analysis of the marker genes peroxi-
some proliferator-activated receptor (PPAR�) and lipopro-
tein lipase (LPL). he primer sequences used for ampliica-
tion of all the genes described above are listed in Table 1.
Aliquots of 10 �L of the ampliication products were analyzed
by 0.8% agarose gel electrophoresis visualized by ethidium-
bromide staining.
3. Results
Small round cell (SCO) sample, obtained by surgical resection
of a part of the tumor (Figure 2) permits the isolation of
only one osteosarcoma cell line (OSA) if treated precisely,
as described before. he number of cells isolated from the
small biopsy is very low (Figure 3). he output range is from
20% to 30% and it depends on the type and the dimension
of the biopsy. For the primary cell line approximately one–
two months is necessary to reach conluence in a 100mm
tissue dish. Ater this period a cell was obtained and marked
as OSA3 (Figures 4(a) and 4(b)). When the cells were grown
they must be subcultured to obtain suicient number of cells
tomake the characterization analyses and to cryopreserve the
primary cell line obtained.
In relation to the characterization of OSA3 as a cell line
of SCO we have evaluated the gene expression of SATB2 and
of EWSR1 by RT-PCR analysis. As showed in Figure 5 OSA3
express both these genes, in particular SATB2. When the
cell line at the 4th passage of subculture reached conluence,
cells were detached and plated in 6-well ultra-low attachment
plates for the sarcosphere assay. his particular type of plate
is used because it permits us to maintain cells in a suspended
state, to prevent stem cells from the attachment-mediated dif-
ferentiation, to prevent the anchorage-dependent cells from
dividing, and, inally, to reduce attachment to the substrate.
Hence, their use permits us to create a stressful conditions
which are necessary to the selection of cancer stem cells
(CSCs). At 24 h ater the start of the assay, cells appear isolated
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Figure 11: Sot agar assay on OSA3, OSA3-CSCs, Saos-2, and PA. Ater 24 h from the setup of the assay cells appear isolated into the agar (a).
Observation in phase contrast. Original magniication 10x. While ater 4 weeks spherical large colonies in OSA3-CSCs and in Saos-2 (b and
d) were formed into the agar, they are absent for OSA3 (c) and PA (e). Observation in phase contrast. Original magniication 20x. Bar size:
100�m.
Figure 12: Sphere formation assay on OSA3-CSCs. Ater 24 h from
the start of the assay, cells appear loating and isolated from each
other (cells are indicated by the black/red arrows). Observation in
phase contrast. Original magniication: 10x. Bar size: 100 �m.
from one another (Figure 6). Ater 14 days of monitoring the
progression of the assay, small spherical colonies have started
to form and are visible. Ater 28 days, several big spherical
colonies that have formed in each well can be observed and
can be isolated (Figures 7(a) and 7(b)). he sarcospheres
isolated were placed in normal attachment 60mm diameter
tissue dishes, under adherent conditions. Figure 8 shows their
adherent expansion in normal attachment plates.
Figure 13: Sphere formation assay on OSA3-CSCs at 14 days.
Ater 14 days from the start of the assay, several small spherical
colonies surrounded by single cells (single cells are indicated by the
black/green arrows) can be observed. he sarcospheres (some of
these are indicated by the black/red arrows) appear loating in the
medium observation in phase contrast. Original magniication: 20x.
Bar size: 100 �m.
Cells that expand from the sarcospheres could be cancer
stem cells. Consequently, ater isolation, the osteosarcoma
cancer stem cells (OSA-CSCs) were probably obtained and
the cell line obtained was marked as OSA3-CSCs (Figure 9).
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Table 1: Detailed list of primer sequences, with the amplicon size and annealing temperature.
Gene Oligonucleotides Sequence (5�-3�)
Amplicon
size (bp)
�� (∘C)
SATB2
Forward
Reverse
TGTCTATCATGTTGTGACGTTGA
TCATCTCTTTGAGCAGTTCCTTTA
150 63
EWS-R1
Forward
Reverse
GCAACAAAGCTATGGAACCTATG
GGGCAGTGGAGTAGTAAACC
137 62
Nanog
Forward
Reverse
CCCAGCTGTGTGTACTCAAT
GGTTCAGGATGTTGGAGAGTT
87 60
POU5F1
Forward
Reverse
GGGAGGAGCTAGGGAAAGA
TCCTTCCTTAGTGAATGAAGAACT
77 60
Sox2
Forward
Reverse
TGCAGTACAACTCCATGA
GGACTTGACCACCGAACC
125 55
KLF4
Forward
Reverse
CGGGAAGGGAGAAGACACT
AGTCGCTTCATG TGGGAGA
79 60
LIN28A
Forward
Reverse
CGACTGTAAGTGGTTCAAC
CCTTCCATGTGCAGCTTACT
100 60
MYC
Forward
Reverse
GCTGCTTAGACGCTGGATTTTT
GAGTCGTAGTCGAGGCATAGT
110 63
PROM1
Forward
Reverse
CCAGAAGCCGGGTCAAAAT
ATTCACTCAAGGCACCATCC
127 60
ALDH1A1
Forward
Reverse
TGATTCAGTGAGTGGCAAGAA
CCTGCAACATCCTCCTTATCT
98 60
CD34
Forward
Reverse
GTACCCTTGGAAGTACCAGCCT
CAGAGGTAGATGTGAATTTGAC
100 60
EZR
Forward
Reverse
GCCTTCTTGTCGATGGGTTA
GCCTCTTGTCGATGGGTTTA
134 61
AXL
Forward
Reverse
TTAGTGCTACGCGGAATGG
CCTATGTCCATAGCACCTCG
133 60
PPAR� Forward
Reverse
GTCGGTTTCAGAAATGCCTTG
ATCTCCGCCAACAGCTTC
97 57
LPL
Forward
Reverse
TGCATTTCAATCACAGCAGCAA
TACAGGGCGGCCACAAG
101 57
Figure 14: Sphere formation assay on OSA3-CSCs ater 30 days.
Ater 30 days big spherical colonies can be observed. Observation
in phase contrast. Original magniication: 20x. Bar size: 100 �m.
As was done for the OSA3 line, it was necessary to make the
OSA3-CSCs line grow and to subculture it, to cryopreserve
this particular cell line, and to obtain the right number of
cells to proceed with the characterization of the stem-like
phenotype.
Figure 15: Cancer stem cell line OSA3-CSCs II. Observation in
phase contrast. Original magniication: 10x. Bar size: 100 �m.
All the analyses of characterization of theOSA3-CSCs cell
line were performed on the 4th passage of subculture ater
the isolation of the sarcospheres. he OSA3-CSCs cell line
showed a doubling time of 167 hours (Figure 10).
he sot agar assay has showed the capacity of the OSA3-
CSCs cell line to grow in sot agar and to form large spherical
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Figure 16: Adipogenic diferentiation assay. Adipogenic diferentiation at 0 days (a-b) and ater 14 days (c-d) of induction by cytochemical
staining with Oil Red O. In red the lipid vesicles and in blue/violet the nuclei, which have been counterstained by hematoxylin. Observation
in brightield. Original magniications: 40x. Bar size: 100 �m.
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Figure 17: Expression of the adipogenic gene markers. RT-PCR
show the expression of PPAR� (let) and LPL (right), two genes
involved into the adipogenic diferentiation.
colonies like the Saos-2 line, compared to the OSA3 and PA
lines (Figures 11(a)–11(e)). he OSA3-CSCs showed a rate of
clonogenic eiciency of 62%, similar to the rate of the SaOS-
2 while the clonogenic eiciency for the OSA3 was less than
10% and was zero for PA. At the 4th passage of subcultured
the OSA3-CSCs were detached and plated in ultra-low
attachment plates to observe if they have maintained their
capacity of self-renew (Figure 12).
Ater 14 days of the sphere formation assay, several small
sarcospheres were observed (Figure 13).
Ater 30 days from the start of the sphere formation assay
several large sarcospheres were observed (Figure 14).
Consequently, the sarcospheres were isolated and plated
in normal adherent conditions.
he sarcospheres were isolated and the cell line was
obtained in normal attachment condition ater the sarco-
spheres isolation was indicated as the second generation of
cancer stem cells from the OSA3 cell line and marked as
OSA3-CSCs II (Figure 15).
OSA3-CSCs II weremade expand to evaluate if the cancer
stem cell phenotype is maintained during the growth of
OSA3-CSCs. Hence, OSA3-CSCs II were evaluated for their
stem cell phenotype as described for their progenitor, the
OSA3-CSCs. Adipogenic diferentiation was not observed in
both OSA3-CSCs and OSA3-CSCs II lines at 0 days, while
ater 30 days of adipogenic induction some cells showed the
presence of intracellular vacuoles containing drops of lipids
of variable shape and size (Figures 16(a)–16(d)).
he adipogenic diferentiation for the OSA3-CSCs line
was conirmed also by RT-PCR of adipocyte-speciic LPL
and PPAR� genes. In the absence of induction, qualitative
RT-PCR showed lack of expression of both these genes,
while ater 30 days of induction, qualitative RT-PCR revealed
a bright and intense band on agarose gel for both genes
(Figure 17).
he osteogenic diferentiation assay showed the capac-
ity of both isolated OSA-CSCs lines to diferentiate into
osteoblast ater 14 days of osteogenic induction.
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Figure 18: Osteogenic diferentiation on OSA3-CSCs and on OSA3-CSCs II lines ALP. Osteogenic diferentiation at 0 days (a-b), ater 14
days (c-d), and ater 21 days of induction by a cytochemical staining for the ALP with Fast Blue BB. In blue the ALP + cells and in red the
nucleus counterstained by Propidium Iodide. Composite observation in brightield and in luorescence. Original magniications: 20x. Bar
size: 100 �m.
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Figure 19: Osteogenic diferentiation on OSA3-CSCs and on OSA3-CSCs II lines HA. Osteogenic diferentiation at 0 days (a-b), ater 14 days
(c-d), and ater 21 days of induction by a cytochemical staining for the hydroxyapatite (HA) with Alizarin Red S.he cells are only contrasted
in blue/grey and the grainy deposits of HA are stained in orange/red. Observation in phase contrast. Original magniications: 20x. Bar size:
100�m.
Ater 21 days of induction both OSA-CSCs lines showed
approximately 90% of the cell population positive to ALP
and showed several calciummineralized deposits. In both the
cell lines the increase of the number of positive cells to ALP
(Figures 18(a)–18(f)) and the production of calcium miner-
alized deposits (Figures 19(a)–19(f)) were time-dependent as
observed.
Furthermore, data obtained by the CFU assay (Figure 20)
have shown a good rate of clonogenic eiciency which is 27%
for OSA3-CSCs and 33% for OSA3-CSCs II.
Several recent studies have shown that high levels of
ALDH activity are characteristic of various types of cancer.
his parameter could be used as a cancer stem cell marker
and with a poor prognosis.
Our ALDH activity assay has showed that the OSA3-CSC
line has high levels of ALDH activity (Figure 21), whereas
ALDH activity was observed at the lower quantiiable limit
in the ibroblast line that was used as a negative control in
this assay. Both OSA3-CSCs and OSA3-CSCs II lines showed
a strong positivity for the surface MSC markers (CD44 and
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Figure 20: Colony forming unit assay. CFU assay on OSA3-CSCs
line stained with Toluidine Blue.
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Figure 21: ALDH activity assay. he ALDH colorimetric assay
detected high levels of ALDH activity in the cell lines of OSA3-CSCs
andOSA6-CSCs while the assay detected the absence of this activity
in the inite diferentiated cell line of ibroblasts, FIB. Error bars: SD.
∗∗p < 0.05 versus FIB.
Table 2: Expression of CD44, CD45, CD105, and CD90 in OSA3,
OSA3-CSCs, and PA lines determined by low cytometry (percent-
age of cells expressing the antigen).
Cell line CD44% CD45% CD105% CD90%
OSA3 99.70 0.00 0.15 14.25
OSA3-CSCs 99.74 0.00 99.52 99.39
PA 99.92 0.00 91.11 99.70
CD105) (Figures 22(a)–22(c) and 23(a)–23(c)), while they
showed a complete negativity or the hematopoietic surface
marker CD45 (Figures 24(a)–24(c)). To evaluate and conirm
the MSC phenotype were also performed low cytometric
analyses on OSA3, OSA3-CSCs, and a mesenchymal stem
cell line of preadipocytes, marked as PA. All the results are
reported in Table 2.
By qualitative RT-PCR analysis we assessed the expres-
sion not only of the ESC marker genes (Nanog, Sox2, KLF4,
LIN28A, and POU5F1) in OSA3, OSA3-CSCs, and OSA3-
CSCs II (Figure 25), but also of the expression of the
pluripotency marker gene, MYC, and of the other speciic
cancer stem cells marker genes (PROM1, ALDH1A1, CD34,
EZR, and AXL) in OSA3 and in OSA3-CSC lines (Figure 26).
Wenoticed that all these genes, which are characteristic of
CSCs phenotype, are expressed in both the OSA3-CSCs lines,
while in the OSA3 line they have resulted to be not expressed
except forNanog, KLF4, POU5F1, AXL, andALDH1A1 genes,
which have been resulted to have only a hard expression.
Furthermore, by the immunoluorescence staining we have
showed the presence and the nuclear localization into the
cells of the ESCs marker genes (Figures 27(a)–27(j)) and
of two important CSCs markers, PROM1 and CD117, which
have been resulted to be localized on the surface of the cells
(Figures 28(a)–28(d)).
4. Discussion
OSA is the most common malignant bone tumor in children
and young adults [1, 2]. his is a tumor which takes origin
from the connective tissue and involve the metaphyseal areas
of the long bones. Despite the fact that it has a low incidence
it is one of the most common primary bone cancers, thus
classiied by the WHO [13]. OSA tumors are a big family
which includes several types of bone injuries.
One of the rarest type of high grade OSA, is the SCO [15–
17]. In 1979 Sim et al. [37] were the irst who for irst used
the term “small cell osteosarcoma” to deine this rare form
of OSA. Nowadays the therapeutic approach to SCO is the
same used for OSA, but the prognosis for those who present
this malignant tumor is always poor.
In the last decades, in the oncologic research ield the new
concept of CSCs has emerged, since in the 1990s they were
identiied and characterized into several tumors [29, 38, 39].
his is a particular cellular cluster which is located inside the
diferentiated tumor bulk and it is responsible to maintain
the homeostasis of the tumor, to give to the malignancy the
possibility of invading other tissues and, in particular, to
preserve and protect the tumor cells from the chemo- and
radiotherapy. All these abilities recognized to the CSCs, in
relation to their stem phenotype, gave a valid explanation for
why tumors, like OSA or SCO, have a poor outcome despite
the neoadjuvant therapies used to treat his malignancies.
he CSCs, as mentioned before, have been just identiied
in several solid tumors [40–43] and, between them, there are
also the bone sarcomas. he identiication of these particular
cells in bone sarcomas, like the OSA [32, 33], has permitted
starting and studying the biology of these tumors using a new
scientiic approach in order to understand the mechanisms
which are behind the chemoresistance of these tumors.
Consequently, to several studies which have identiied
CSCs in OSA, we have decided to investigate the presence of
the CSCs in SCO. We have had the possibility of obtaining a
fresh sample of tissue of SCO, from which we have isolated
a inite cell line, marked as OSA3. Ater the conirmation, by
the pathologist, of the tissue histotype and the establishment
of the OSA3, we have evaluated the phenotype of our cell line.
We have observed in OSA3 line not only a strong expression
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Figure 22: Immunoluorescence staining of CD44. Immunoluorescence staining of CD44 of the cell lines of OSA-CSCs, OSA3-CSCs (a)
and OSA3-CSCs II (b). (c) Negative control. LSCM in conventional colors: green for CD44 and blue for nuclei. Original magniications: 20x.
Bar size: 100 �m.
(a) (b) (c)
Figure 23: Immunoluorescence staining of CD105. Immunoluorescence staining of CD105 of the cell lines of OSA-CSCs, OSA3-CSCs (a)
and OSA3-CSCs II (b). (c) Negative control. LSCM in conventional colors: green for CD105 and blue for nuclei. Original magniications: 20x.
Bar size: 100 �m.
(a) (b) (c)
Figure 24: Immunoluorescence staining of CD45. Immunoluorescence staining of CD45 of the cell lines of OSA-CSCs, OSA3-CSCs (a) and
OSA3-CSCs II (b). (c) Negative control. LSCM in conventional colors: green for CD45 and blue for nuclei. Original magniications: 20x. Bar
size: 100 �m.
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Figure 25: Expression of the nuclear ESC marker genes. RT-PCR
show the expression of POU5F1, Nanog, LIN28A, and KLF4 in
OSA3-CSCs, in OSA3-CSCs II, and in OSA3.
O
SA
3
O
SA
3-
C
SC
s
�-actin
ALDH1A1
MYC
PROM1
AXL
EZR
CD34
Figure 26: Expression of the cancer stem cells marker genes. RT-
PCR show the expression of PROM1, MYC, ALDH1A1, CD34, EZR,
and AXL in OSA3-CSCs and in OSA3.
of the marker gene for the osteoblast diferentiation, SATB2,
but also a minimal expression of the EWSR1 gene, which is
the principle marker gene for the Ewing Sarcoma [44].
Despite these particular aspects, some recent studies have
reported the efective presence of EWSR1 rearrangements in
few cases of SCO [45, 46] and it needs to bemore investigated
to understand the possible importance of this particular gene
into the biology of SCO.
Ater all the cellular and tissue characterization of SCO,
we have proceeded to investigate the stemness of the OSA3
line.
On the base of the experiments reported by Gibbs et
al. [35], in relation to the possibility of isolating the CSCs
by using the capacity of stem cells to survive and grow in
extreme condition, like nonadherent conditions, we have
isolated from the OSA3 line a cancer stem cell line, marked
as OSA3-CSCs II. We have successfully established a OSA3-
CSCs inite cell line and also characterized this as a real CSCs
line, studying both the embryonic and themesenchymal stem
phenotype which characterized the CSCs [29].
It has been observed that OSA3-CSCs at the 4th passage
of subculture were able to self-renew; in fact the sphere
formation assay setup has showed their capacity to grow
in nonadherent conditions and to generate several large
sarcospheres, which have given origin to the “second” gen-
eration of CSCs of SCO. Our diferentiation experiments
have conirmed the capacity of both the CSCs lines to
diferentiate in the mesodermal lineages of osteoblasts and
adipocytes, as can be done by the mesenchymal stem cells
like the preadipocytes. he mesenchymal stem phenotype
has been also conirmed by the clonogenic eiciency and in
particular by the data obtained by low cytometry on the
expression of the epithelial-speciic antigens CD44, CD105
and CD90, which, if they are both expressed, are recognized
to be mesenchymal stem cells (MSCs) markers. Data showed
that our OSA3-CSCs population isolated by the sarcospheres
assay is totally positive to their presence, compared to the
primary culture of SCO, which has been resulted to be
very positive only to the presence of CD44. Hence, the
low cytometric analysis has showed that OSA3-CSCs line
has a stemness phenotype comparable to preadipocytes. he
membrane localization of the two MSCs markers is also
showed by the immunoluorescence staining, which has
conirmed the total absence of the other hematopoietic-
speciic antigen CD45. his is another important data that
conirms the mesenchymal stemness of OSA3-CSCs line.
Additionally, we have evaluated and conirmed their
embryonal stemness, the other aspect which characterizes the
CSCs. Both theOSA3-CSCs lines have showed the expression
of all the ive genes which are related to the embryonic
stemness (Nanog, Sox2, POU5F1, KL4, and LIN28A), while
they are only a few expressed in OSA3 line. hey are deined
as the genes of the transcriptional core which is entirely
responsible for the maintenance of the pluripotency in the
embryonic cells [47–54]. So, the expression of all these genes
in the CSCs has been recognized to be the base for their
stem phenotype and for their ability to self-renew, not only
themselves but all the tumor bulk in which these cells are
included.
he embryonic stem phenotype has been also conirmed
by the study of the nuclear localization of the embryonic stem
cells (ESCs) markers by the immunoluorescence staining.
Since this small subpopulation has this particular prop-
erty, the tumor can be resistant to the diferent therapies until
the small cluster will not eradicated. In our study we have
also characterized the malignant phenotype of the OSA3-
CSCs by the analysis of the activity and the expression of
aldehyde dehydrogenase 1 family, member A1 (ALDH1A1)
a detoxiication enzyme, which is responsible for the tumor
resistance to cytotoxic chemotherapy [55]. Furthermore,
only in the malignancies, we can observed high levels of
ALDH1A1, and in particular in the CSCs in relation to their
capacity to protect the other diferentiated cancer cells.
Moreover, we have demonstrated the gene expression of
another three very important genes in the characterization
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Figure 27: Immunoluorescence staining of ESCsmarkers. Immunoluorescence staining of Nanog (a), POU5F1 (c), SOX2 (e), KLF4 (g), and
LIN-28A (i) of the cell line of OSA3-CSCs. (b, d, f, h, and j) Negative controls, respectively, for each marker. LSCM in conventional colors:
green for ESCs and pink for nuclei. Original magniications: 20x. Bar size: 100 �m.
of the cancer stem cells. he PROM1 gene, also known as
CD133+, is one of the principal markers of osteosarcoma
cancer stem cells [32, 33] together with CD34, a marker of the
undiferentiated state of the cells, and the ALDH1A1 genes. At
the same time, we have observed the absence of these genes
into the OSA3 line. Contemporary, we have also study the
presence of CD133 and of CD117, other important cancer stem
cells markers in osteosarcoma [55], on the surface of OSA3-
CSCs, by the immunoluorescence staining.
Aterwards we have investigated also the presence of two
other genes which recently have been linked to the CSCs, the
EZR and the AXL genes which encode for two proteins which
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Figure 28: Immunoluorescence staining of CD117 and PROM1. Immunoluorescence staining of CD117 (a) and of PROM1 (c) of the cell
line of OSA3-CSCs. (b and d) Negative controls, respectively, for each marker. LSCM in conventional colors: green for ESCs and sky blue for
nuclei. Original magniications: 20x. Bar size: 100 �m.
have been observed to be related to the malignant phenotype
of a tumor [56–58]; these are involved and probably are key
molecules, in the process of migration and of invasiveness
operated by the CSCs. In addition to this, we have evaluated
the efective capacity of the OSA3-CSCs to form colonies
in agar sot assay, which is the most well established and
rigorous in vitro assay to test the malignant transformation
and the capacity to invade others tissues. Property is absent
in the mesenchymal stem cells, as demonstrated by the data
obtained. Hence, the data showed in vitro are predictive of the
capacity to relapse the SCO, as described in several studies
[16–20].
5. Conclusions
To develop an efective therapeutic strategy against OSA,
and in particular against the typologies which are more
aggressive and with a poor prognosis as the SCO, it is
necessary not only to know the origin of this pathology,
but also to understand which are the internal mechanisms
responsible for the recurrence and for the invasiveness of
these bone tumors. he discovery of the cluster of the cancer
stem cells inside the tumors has represented the possibility
of studying the mechanisms responsible for their resistance
to the therapies. Consequently, our principal aim has been to
demonstrate the presence of stemness into one of the rarer
and aggressive histotypes of OSA.
In this research, we have collected and established a
human primary cell line of SCO. Additionally, we have
provided the evidence of the existence of the CSCs in SCO,
too. Here, we have aimed to characterize the OSA3-CSCs line
as a cellular model of humanCSCs selected from primary cell
line of small round cells osteosarcoma.
For the irst time, we have established a CSCs line of this
rare type of OSA and we have proved their in vitro features of
CSCs.
In conclusion, our research aims to be an important
irst step to study in vitro the biology and the molecular
mechanismswhich are linked to the CSCs phenotype in SCO,
with the principal aim to identify new molecular biomarkers
cancer related. Nowadays one of the most common and
famous molecular biomarkers is the large family of the small
noncoding RNA, and in particular the micro RNAs (miR-
NAs), small interfering RNA (siRNA) and other classes of
small molecules [59–62]. Several studies have demonstrated
their importance in the development of the tumors and
in the maintenance of their stemness [63–66], but on the
other hand they have also demonstrated how these small
molecules can be used as target against the maintenance
of the stem phenotype of putative CSCs, representing a
possible instrument against the stem cluster of a cancer [67–
72]. Consequently, we have established a cellular model of
CSCs from one of the rarer forms of OSA to study the
presence of these targets and of their efect on his proved
cancer stem phenotype with the hope to pave the way
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to the development of more efective focused therapeutic
strategies for small cell osteosarcoma, with this still being
not investigated thoroughly with an unfavorable prognosis
despite the aggressive multitherapeutic approach.
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